Anticoagulation and Antiplatelet Management During Perioperative Period

Completed

• Conditions: Anticoagulants and Bleeding Disorders

• Registration Number: NCT03871283
• Lead Sponsor: Erasme University Hospital

Brief Summary

the investigators hypothesize that patients do not understand these therapies, and that they are poorly undertaken. In some cases, the anesthesiologist does not understand correctly the indication of the treatment due to lack of information and therefore does not know how to adapt it to the medical situation.

Detailed Description

the investigators hypothesize that patients do not understand these therapies, and that they are poorly undertaken. In some cases, the anesthesiologist does not understand correctly the indication of the treatment due to lack of information and therefore does not know how to adapt it to the medical situation.

the investigators want to investigate these transitions: how were they understood by patients, how were they performed, and how does this affect surgery, postoperative morbidity and mortality?

Anticoagulation for prevention of thromboembolic events will not be studied in this study.

The anesthesia team will not be particularly trained in anticoagulants and antiplatelets management to be close to actual care. In the Hospital the investigators have a guide written in 2013 in order to describe all the cases possible. The "control/ goal group" will be the patients who have undertaken strictly the protocol described for their cases in the guide.

Study Timeline

• Study Start: 2019-01-01
• Study First Submitted: 2019-02-19
• Study First Submitted QC: 2019-03-11
• Study First Posted: 2019-03-12
• Primary Completion: 2019-12-31
• Study Completion: 2019-12-31
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-11
• Last Update Posted: 2020-08-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2400

Inclusion Criteria

• Patients over 18 years old
• Able to consent
• Taking anticoagulants or antiplatelet drugs in the long term.

Exclusion Criteria

• Incapacitated adults
• Minor patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ratio of well treated patient	30 days	Ratio of well treated patient

Secondary Outcome Measures

Name	Time	Method
bleeding consequence (volume in mL)	30 days	bleeding consequence (volume in mL)
Mortality Consequence	30 Days	percentage of death
Blood Test Consequence	30 Days	deviation in percentage on INR
Morbidity	30 days	percentage of rehospitalisation

Trial Locations

Locations (1)

ERASME Hospital; 🇧🇪 Bruxelles, Belgium